Caption Management, LLC Immunovant, Inc. Put Options Transaction History

Caption Management, LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$27.51 - $27.51 $415,401 - $415,401	-15,100 Reduced 23.2%	50,000 $1.38 Million
Q2 2024 Aug 14, 2024	SELL	$25.1 - $31.61 $2.88 Million - $3.63 Million	-114,900 Reduced 63.83%	65,100 $1.72 Million
Q1 2024 May 15, 2024	BUY	$30.27 - $43.79 $4.54 Million - $6.57 Million	150,000 Added 500.0%	180,000 $5.82 Million
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $29.7 Million - $41.9 Million	-947,500 Reduced 96.93%	30,000 $1.26 Million
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $17.8 Million - $38.4 Million	960,000 Added 5485.71%	977,500 $37.5 Million
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $267,225 - $345,100	17,500 New	17,500 $271,000
Q1 2021 May 17, 2021	BUY	$13.08 - $49.6 $1.11 Million - $4.2 Million	84,700 New	84,700 $1.36 Million

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.